Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: Comparative post hoc analyses

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 1737-1750

  Ciudad, Antonio ^a   Anand, Ernie ^b   Berggren, Lovisa ^c   Casillas, Marta ^a   Schacht, Alexander ^c   Perrin, Elena ^b  

^a ELI LILLY AND COMPANY   (Spain)

^b ELI LILLY AND COMPANY   (United States)

^c LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Depot formulation; Long acting injection; Olanzapine; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; GLUCOSE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LONG ACTING DRUG; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

ACUTE DISEASE; ADULT; AGITATION; ANXIETY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERLIPIDEMIA; INCREASED APPETITE; INSOMNIA; LETHARGY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTPATIENT; PARKINSONISM; PHASE 3 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SORE THROAT; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84887400433     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S50635     Document Type: Article

References (29)

1. Falkai P, Wobrock T, Lieberman J, etal. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry. 2006;7:5-40.
2. Kane JM, Leucht S, Carpenter D; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64 Suppl 12:S5-S19.
3. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007;115:260-267.
4. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry. 2003;64 Suppl 16:S34-S40.
5. Patel MX, Taylor M, David AS. Antipsychotic long-acting (depot) injections for the treatment of schizophrenia. Br J Psychiatry. 2009;195:S1-S57.
6. Taylor M, Ng KY. Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review. Aust N Z J Psychiatry. 2013;47:624-630.
7. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603-609.
8. Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69:790-799.
9. Kane JM, Detke HC, Naber D, etal. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167:181-189.
10. Detke H, Weiden PJ, Lambert T, etal. Olanzapine long-acting injection vs oral olanzapine in schizophrenia outpatients: a 2-year, randomized, open-label study. Eur Neuropsychopharmacol. 2010;20:S464.
11. ClinicalTrials. gov. Olanzapine pamoate depot versus oral olanzapine on treatment outcomes in outpatients with schizophrenia. Available from: http://clinicaltrials.gov/show/NCT00320489. Accessed January 31, 2013.
12. Lieberman JA, Stroup TS, McEvoy JP, etal; for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
13. Kahn RS, Fleischhacker WW, Boter H, etal; for EUFEST Study Group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085-1097.
14. Ascher-Svanum H, Montgomery WS, McDonnell DP, Coleman KA, Feldman PD. Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons. Int J Gen Med. 2012;5:391-398.
15. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
16. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education and Welfare; 1976.
17. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
18. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
19. Tiihonen J, Wahlbeck K, Lönnqvist J, etal. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333:224.
20. Beasley CM Jr, Stauffer VL, Liu-Seifert H, Taylor CC, Dunayevich E, Davis JM. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol. 2007;27:252-258.
21. Leucht S, Komossa K, Rummel-Kluge C, etal. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166:152-163.
22. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.
23. Olanzapine long-acting injection. Summary of Product Characteristics. July 11, 2012. Available from: http://www.medicines.org.uk/EMC/medicine/21361/SPC/ZYPADHERA+210+mg%2c+300+mg%2c+and+405+mg%2c+powder+and+solvent+for+prolonged+release+suspension+for+injection/. Accessed February 8, 2013.
24. Olanzapine. Summary of Product Characteristics. July 11, 2012. Available from: http://www.medicines.org.uk/EMC/medicine/614/SPC/Zyprexa++2.5 mg%2c+5 mg%2c+7.5 mg%2c+10 mg%2c+15 mg%2c++and+20 mg+coated+tablets.+Zyprexa+Velotab++5 mg%2c+10 mg%2c+15 mg%2c++and+20 mg++orodispersible+tablets/. Accessed February 8, 2013.
25. Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010;30:531-540.
26. Komossa K, Rummel-Kluge C, Hunger H, etal. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;3:CD006654.
27. Krzystanek M, Krupka-Matuszczyk I. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Hum Psychopharmacol. 2011;26:81-85.
28. Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL. Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database. J Psychopharmacol. 2013;27:358-365.
29. Hill AL, Sun B, Karagianis JL, Watson SB, McDonnell DP. Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. BMC Psychiatry. 2011;11:28.